Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Malignant Melanoma

Free Subscription Articles published in Melanoma Res Retrieve available abstracts of 172 articles: HTML format

Single Articles

August 2025
1. VAN AMMERS M, Tracey T, Yazdabadi A, Ciconte A, et al
   A survey of skin check rates in an outpatient oncology melanoma clinic.
   Melanoma Res. 2025;35:290-291.
   PubMed    
   
   
   July 2025
2. CHAI Y, Zhao J, Wang X, Li B, et al
   Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas.
   Melanoma Res. 2025 Jul 1. doi: 10.1097/CMR.0000000000001051.
   PubMed     Abstract available
   
   
   June 2025
3. KRISTJANSEN KA, Birk-Sorensen L, Bonnelykke-Behrndtz ML
   Perioperative neutrophil-to-lymphocyte ratio in patients with melanoma: a pilot study assessing surgical stress after sentinel lymph node biopsy.
   Melanoma Res. 2025 Jun 26. doi: 10.1097/CMR.0000000000001052.
   PubMed     Abstract available
   
   
   
4. PANDIT-TASKAR N, Mauguen A, Frosina D, Jungbluth A, et al
   Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study.
   Melanoma Res. 2025 Jun 25. doi: 10.1097/CMR.0000000000001050.
   PubMed     Abstract available
   
   
   
5. KREUZ M, Moraes FCA, Lobo AOM, Skov RPH, et al
   Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors.
   Melanoma Res. 2025 Jun 6. doi: 10.1097/CMR.0000000000001049.
   PubMed     Abstract available
   
   
   
6. BERKAOUI I, Zourdani L, Janela-Lapert R
   Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma.
   Melanoma Res. 2025 Jun 4. doi: 10.1097/CMR.0000000000001048.
   PubMed     Abstract available
   
   
   
7. CHAVERON M, Toulemonde E, Desmedt E, Boileau M, et al
   Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma.
   Melanoma Res. 2025;35:213-215.
   PubMed    
   
   
   May 2025
8. BERTOLLI E, Micheletti SB, de Camargo VP, da Silva TV, et al
   Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?
   Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001047.
   PubMed     Abstract available
   
   
   
9. KREUZ M, de Souza Wagner PH, Tanimoto LE, da Rosa VA, et al
   Melanoma and pregnant women: a systematic review and meta-analysis.
   Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001043.
   PubMed     Abstract available
   
   
   
10. BLOHOWIAK RF, Welch NW, Rigden BW, Varman RM, et al
    Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study.
    Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001046.
    PubMed     Abstract available
    
    
    
11. MYNAM RS, Menon N, Birbrair A, Ma VT, et al
    Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma.
    Melanoma Res. 2025 May 27. doi: 10.1097/CMR.0000000000001045.
    PubMed     Abstract available
    
    
    
12. VAN RYAN V, Zahrieh D, Strand C, Churchill RA, et al
    Impact of systemic imaging surveillance on survival from metastatic uveal melanoma.
    Melanoma Res. 2025 May 19. doi: 10.1097/CMR.0000000000001042.
    PubMed     Abstract available
    
    
    
13. PALACIOS-DIAZ RD, de Unamuno-Bustos B, Carratala-Garcia A, Perez-Simo G, et al
    Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma.
    Melanoma Res. 2025 May 19. doi: 10.1097/CMR.0000000000001041.
    PubMed     Abstract available
    
    
    April 2025
14. JOERGER M, Diem S, Wyss N, Koster KL, et al
    Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA).
    Melanoma Res. 2025 Apr 17. doi: 10.1097/CMR.0000000000001040.
    PubMed     Abstract available
    
    
    
15. ACAR C, Yuksel HC, Sahin G, Acar FP, et al
    C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2025 Apr 8. doi: 10.1097/CMR.0000000000001039.
    PubMed     Abstract available
    
    
    
16. MATTEI J, Trindade EN, Chedid MF
    Mucosal melanoma: from molecular landscape to current treatment strategies: Erratum.
    Melanoma Res. 2025;35:153.
    PubMed    
    
    
    
17. MARSIGLIO J, McPherson J, Wahl M, Hu-Lieskovan S, et al
    Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature.
    Melanoma Res. 2025;35:109-114.
    PubMed     Abstract available
    
    
    
18. DAVIDSON SJ, Teoh DGK, Dudek AZ, Vogel RI, et al
    Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis.
    Melanoma Res. 2025 Apr 1. doi: 10.1097/CMR.0000000000001036.
    PubMed     Abstract available
    
    
    
19. PEDERSEN S, Borch TH, Svane IM, Donia M, et al
    Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.
    Melanoma Res. 2025 Apr 1. doi: 10.1097/CMR.0000000000001037.
    PubMed     Abstract available
    
    
    March 2025
20. BUJA A, Rugge M, Formaro CM, Grotto G, et al
    A real-world direct cost associated with a 4-year postdiagnosis follow-up in a population-based cohort of patients with melanoma by clinical-pathological characteristics.
    Melanoma Res. 2025 Mar 28. doi: 10.1097/CMR.0000000000001033.
    PubMed     Abstract available
    
    
    
21. HINNEN C, Tijssens F, von Haeseler E, van de Berg S, et al
    Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study.
    Melanoma Res. 2025 Mar 25. doi: 10.1097/CMR.0000000000001035.
    PubMed     Abstract available
    
    
    
22. GUYON M, Faure M, Pernot M, Pham-Ledard A, et al
    Management of cardiac metastases of melanoma in the era of immunotherapy: a case series.
    Melanoma Res. 2025 Mar 25. doi: 10.1097/CMR.0000000000001032.
    PubMed     Abstract available
    
    
    
23. TAS F, Ahishali E, Taskin OC
    Nivolumab-induced immune-mediated acute gastritis in a melanoma patient.
    Melanoma Res. 2025 Mar 21. doi: 10.1097/CMR.0000000000001034.
    PubMed     Abstract available
    
    
    February 2025
24. JANSSEN S, Moufarrej A, Springer R, Haberle L, et al
    Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors.
    Melanoma Res. 2025 Feb 27. doi: 10.1097/CMR.0000000000001028.
    PubMed     Abstract available
    
    
    
25. GUGLIELMO A, De Benedittis A, Buligan C, Zelin E, et al
    Multiple primary melanomas in Udine, northeastern Italy: a focus on epidemiology and new risk factors.
    Melanoma Res. 2025 Feb 27. doi: 10.1097/CMR.0000000000001029.
    PubMed     Abstract available
    
    
    
26. BEITNER A, Abu-Abeid A, Dayan D, Gat A, et al
    Patterns of expression and prognostic implication of glycoprotein nonmetastatic protein B (GPNMB) expression in sentinel lymph nodes of melanoma patients.
    Melanoma Res. 2025 Feb 14. doi: 10.1097/CMR.0000000000001019.
    PubMed     Abstract available
    
    
    
27. AMRANE K, Le Noac'h P, Hemon P, Abgral R, et al
    MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors.
    Melanoma Res. 2025 Feb 12. doi: 10.1097/CMR.0000000000001022.
    PubMed     Abstract available
    
    
    
28. GONZALEZ-BARRALLO I, Castellon Rubio VE, Medina J, Espana Fernandez S, et al
    Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study.
    Melanoma Res. 2025 Feb 7. doi: 10.1097/CMR.0000000000001020.
    PubMed     Abstract available
    
    
    
29. KERKOUR T, Meijers RWJ, Hollestein LM, Jansen AML, et al
    Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases.
    Melanoma Res. 2025 Feb 6. doi: 10.1097/CMR.0000000000001024.
    PubMed     Abstract available
    
    
    
30. TAS F, Erturk K
    Brain metastases during follow-up of patients with resected cutaneous melanoma.
    Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001026.
    PubMed     Abstract available
    
    
    
31. BHATT KA, Vaynrub AJ, Cham J, Iyer SG, et al
    Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia.
    Melanoma Res. 2025 Feb 4. doi: 10.1097/CMR.0000000000001025.
    PubMed     Abstract available
    
    
    
32. SHEN YC, Huang YL, Kang YN, Chiu WK, et al
    Effectiveness and safety of talimogene laherparepvec and granulocyte-macrophage colony-stimulating factor for metastatic melanoma: a systematic review and network meta-analysis of randomized controlled trials.
    Melanoma Res. 2025;35:60-66.
    PubMed     Abstract available
    
    
    January 2025
33. ANGELL CD, Sun SH, Lapurga G, Benner B, et al
    A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade.
    Melanoma Res. 2025 Jan 29. doi: 10.1097/CMR.0000000000001023.
    PubMed     Abstract available
    
    
    
34. CHEN L, Cai B, Ni X, Lin Q, et al
    Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety.
    Melanoma Res. 2025 Jan 28. doi: 10.1097/CMR.0000000000001021.
    PubMed     Abstract available
    
    
    
35. BASSI V, Apuzzi V, Vanella V, Facchini BA, et al
    SIAD onset in a patient affected by metastatic melanoma treated with immune checkpoint inhibitors: the role of nivolumab treatment.
    Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001017.
    PubMed    
    
    
    
36. POZUELO-RUIZ M, de Unamuno-Bustos B, Palacios-Diaz RD, Blanes-Martinez MDM, et al
    Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals.
    Melanoma Res. 2025 Jan 7. doi: 10.1097/CMR.0000000000001018.
    PubMed     Abstract available
    
    
    December 2024
37. AL-NAESAN I, Krepper D, Sparano F, Sztankay M, et al
    Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results.
    Melanoma Res. 2024 Dec 11. doi: 10.1097/CMR.0000000000001014.
    PubMed     Abstract available
    
    
    
38. LEIBOVIT-REIBEN Z, Godfrey H, Jedlowski P, Thiede R, et al
    Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.
    Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001015.
    PubMed     Abstract available
    
    
    
39. ESMAELI B, Ogden T, Nichols M, Lu T, et al
    Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma.
    Melanoma Res. 2024 Dec 6. doi: 10.1097/CMR.0000000000001016.
    PubMed     Abstract available
    
    
    
40. WITTEVEEN SJ, Klop WMC, van Dijk-de Haan MC, Karssemakers LHE, et al
    Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I-II.
    Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001013.
    PubMed     Abstract available
    
    
    
41. HORISAKI K, Yoshikawa S, Omata W, Tsutsumida A, et al
    Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study.
    Melanoma Res. 2024 Dec 3. doi: 10.1097/CMR.0000000000001012.
    PubMed     Abstract available
    
    
    
42. BURSHTEIN J, Shah M, Zakria D, Rigel D, et al
    The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio.
    Melanoma Res. 2024;34:550-552.
    PubMed    
    
    
    
43. ARJUNAN A, Wardrop M, Malek MM, Davit AJ 3rd, et al
    Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients.
    Melanoma Res. 2024;34:544-548.
    PubMed     Abstract available
    
    
    November 2024
44. NIU L, Liu S, Shen J, Chang J, et al
    ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells.
    Melanoma Res. 2024 Nov 26. doi: 10.1097/CMR.0000000000001011.
    PubMed     Abstract available
    
    
    
45. MACAIRE C, Lefevre W, Dalac S, Montaudie H, et al
    Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.
    Melanoma Res. 2024 Nov 11. doi: 10.1097/CMR.0000000000000973.
    PubMed     Abstract available
    
    
    October 2024
46. ZHENG L, Susanto AK, Soyer HP, Janda M, et al
    Psychosocial wellbeing in people with melanoma in-situ: a systematic review.
    Melanoma Res. 2024 Oct 10. doi: 10.1097/CMR.0000000000001007.
    PubMed     Abstract available
    
    
    
47. KREUZ M, de Moraes FCA, Sano VKT, Westphal Filho FL, et al
    Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis.
    Melanoma Res. 2024 Oct 8. doi: 10.1097/CMR.0000000000001006.
    PubMed     Abstract available
    
    
    
48. CAMPILLO P, Kesler A, Ramirez CA, Ramirez CJ, et al
    International incidence of melanoma in heart transplant recipients: a meta-analysis.
    Melanoma Res. 2024 Oct 7. doi: 10.1097/CMR.0000000000001008.
    PubMed     Abstract available
    
    
    
49. PAOLINO G, Podo Brunetti A, De Rosa C, Cantisani C, et al
    Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma.
    Melanoma Res. 2024 Oct 4. doi: 10.1097/CMR.0000000000001003.
    PubMed     Abstract available
    
    
    
50. 
    Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma: Erratum.
    Melanoma Res. 2024;34:473.
    PubMed    
    
    
    
51. MATTIUZZI C, Lippi G
    The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic.
    Melanoma Res. 2024;34:472.
    PubMed    
    
    
    September 2024
52. NACCHIERO E, Giotta M, Robusto F, Metta ME, et al
    The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease.
    Melanoma Res. 2024 Sep 25. doi: 10.1097/CMR.0000000000000999.
    PubMed     Abstract available
    
    
    
53. STAWIARZ M, Hoang MP, Kowalik A
    High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma.
    Melanoma Res. 2024 Sep 18. doi: 10.1097/CMR.0000000000001005.
    PubMed     Abstract available
    
    
    
54. MCKECHNIE T, Talwar G, Grewal S, Wang A, et al
    The impact of statins on melanoma survival: a systematic review and meta-analysis.
    Melanoma Res. 2024 Sep 12. doi: 10.1097/CMR.0000000000001001.
    PubMed     Abstract available
    
    
    August 2024
55. STOFF R, Markovic SN, McWilliams RR, Kottschade LA, et al
    Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000000997.
    PubMed     Abstract available
    
    
    
56. KIM I, Oh J, Yoon S, Han MY, et al
    Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004-2019).
    Melanoma Res. 2024 Aug 30. doi: 10.1097/CMR.0000000000001000.
    PubMed     Abstract available
    
    
    
57. ZWEEDIJK BE, Schurink AW, van Dalen T, van Ginhoven TM, et al
    Transcutaneous sentinel lymph node detection in skin melanoma with near-infrared fluorescence imaging using indocyanine green.
    Melanoma Res. 2024 Aug 2. doi: 10.1097/CMR.0000000000000994.
    PubMed     Abstract available
    
    
    
58. WANG S, Zhou H, Ma Y, Jin S, et al
    A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site.
    Melanoma Res. 2024;34:390-392.
    PubMed    
    
    
    
59. KIBBIE JJ, Zita SM, Dellavalle RP, Dunnick CA, et al
    The number needed to biopsy for cutaneous melanoma in academic dermatology clinics.
    Melanoma Res. 2024;34:350-354.
    PubMed     Abstract available
    
    
    
60. ORLANDI E, Ceccuzzi L, Belpinati F, Rodolfo M, et al
    Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and the impact of sex hormones in gene expression in skin cells.
    Melanoma Res. 2024;34:296-306.
    PubMed     Abstract available
    
    
    
61. OZLUK AA, Gunenc D, Yildirim SS, Karaca B, et al
    Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature.
    Melanoma Res. 2024;34:335-342.
    PubMed     Abstract available
    
    
    July 2024
62. ZHANG S, Liu Z, Zhu D
    Development and validation of prognostic nomogram in pediatric melanoma: a population-based study.
    Melanoma Res. 2024 Jul 31. doi: 10.1097/CMR.0000000000000993.
    PubMed     Abstract available
    
    
    
63. ELMES JB, Davis JM, Musselwhite LW, Chiad Z, et al
    Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000992.
    PubMed     Abstract available
    
    
    
64. TSIMPIDAKIS A, Koumprentziotis IA, Mastoraki E, Plaka M, et al
    Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight.
    Melanoma Res. 2024 Jul 22. doi: 10.1097/CMR.0000000000000991.
    PubMed     Abstract available
    
    
    
65. CHANDRASEKARAN S, Ling YL, Tang J
    Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF-mutated melanoma patients in the United States.
    Melanoma Res. 2024 Jul 16. doi: 10.1097/CMR.0000000000000990.
    PubMed     Abstract available
    
    
    
66. FOKKEN C, Silbern I, Shomroni O, Pan KT, et al
    Interfering with aggregated alpha-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins.
    Melanoma Res. 2024 Jul 2. doi: 10.1097/CMR.0000000000000982.
    PubMed     Abstract available
    
    
    June 2024
67. LOCHRIN SE, Cugliari MK, Yeh R, Shoushtari AN, et al
    Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma.
    Melanoma Res. 2024 Jun 28. doi: 10.1097/CMR.0000000000000988.
    PubMed     Abstract available
    
    
    
68. DE GIORGI V, Cecchi G, Perillo G, Zuccaro B, et al
    Synchronous double primary vulvar melanoma: a not so rare possibility. A clinical and dermoscopic case study.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000989.
    PubMed     Abstract available
    
    
    
69. ASHER N, Bar-Hai N, Ben-Betzalel G, Stoff R, et al
    Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy.
    Melanoma Res. 2024 Jun 24. doi: 10.1097/CMR.0000000000000985.
    PubMed     Abstract available
    
    
    
70. SHEMER M, Shimonovitz M, Furer R, Abu-Abeid A, et al
    Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.
    Melanoma Res. 2024 Jun 14. doi: 10.1097/CMR.0000000000000986.
    PubMed     Abstract available
    
    
    
71. BUSTAMANTE P, Coblentz J, Mastromonaco C, Youhnovska E, et al
    Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model.
    Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000964.
    PubMed     Abstract available
    
    
    
72. LIU H, Jiang H, Shan Q
    Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis.
    Melanoma Res. 2024 Jun 7. doi: 10.1097/CMR.0000000000000980.
    PubMed     Abstract available
    
    
    
73. LUO P, Guo R, Gao D, Zhang Q, et al
    Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study.
    Melanoma Res. 2024 Jun 5. doi: 10.1097/CMR.0000000000000983.
    PubMed     Abstract available
    
    
    
74. DINI F, Susini P, Zuccaro B, Nisi G, et al
    Head and neck melanoma: the eyelid region has a better prognosis and easier management: a retrospective survey and systematic review.
    Melanoma Res. 2024 Jun 3. doi: 10.1097/CMR.0000000000000984.
    PubMed     Abstract available
    
    
    
75. SHAH H, Parisi R, Everdell E, Feustel P, et al
    The effect of COVID-19 on early melanoma detection.
    Melanoma Res. 2024;34:283-284.
    PubMed    
    
    
    May 2024
76. SAMLOWSKI W, Silver MA, Hohlbauch A, Zhang S, et al
    Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma.
    Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000962.
    PubMed     Abstract available
    
    
    
77. VANDER MIJNSBRUGGE AS, Cerckel J, Dirven I, Tijtgat J, et al
    Regorafenib in patients with pretreated advanced melanoma: a single-center case series.
    Melanoma Res. 2024 May 27. doi: 10.1097/CMR.0000000000000977.
    PubMed     Abstract available
    
    
    
78. INDINI A, Gueli R, Cerati M, Rijavec E, et al
    Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma.
    Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000981.
    PubMed     Abstract available
    
    
    
79. ALBERTINI MR, Zuleger CL, Ranheim EA, Shiyanbola O, et al
    Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.
    Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000975.
    PubMed     Abstract available
    
    
    April 2024
80. GAO Y, Wang Y, Luo Y, Zhang Y, et al
    Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.
    Melanoma Res. 2024 Apr 22. doi: 10.1097/CMR.0000000000000972.
    PubMed     Abstract available
    
    
    
81. WU LW, Tao JJ, McDonnell D, Izar B, et al
    Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
    Melanoma Res. 2024 Apr 18. doi: 10.1097/CMR.0000000000000974.
    PubMed     Abstract available
    
    
    
82. SUWAJANAKORN D, Lane AM, Go AK, Hartley CD, et al
    Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma.
    Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000971.
    PubMed     Abstract available
    
    
    
83. HENNEMANN A, Puzenat E, Decreuse M, Vuillier F, et al
    Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
    Melanoma Res. 2024 Apr 5. doi: 10.1097/CMR.0000000000000820.
    PubMed     Abstract available
    
    
    
84. MAIONE V, Perantoni M, Bettolini L, Bighetti S, et al
    Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients.
    Melanoma Res. 2024 Apr 2. doi: 10.1097/CMR.0000000000000970.
    PubMed     Abstract available
    
    
    March 2024
85. KODALI N, Bhattaru A, Blanchard I, Sharma Y, et al
    Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis.
    Melanoma Res. 2024 Mar 29. doi: 10.1097/CMR.0000000000000968.
    PubMed     Abstract available
    
    
    
86. FABRE M, Lamoureux A, Meunier L, Samaran Q, et al
    Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
    Melanoma Res. 2024 Mar 28. doi: 10.1097/CMR.0000000000000963.
    PubMed     Abstract available
    
    
    
87. NEKKANTI SS, Nusrath S, Jarang R, Rayani BK, et al
    Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity.
    Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000967.
    PubMed     Abstract available
    
    
    
88. LEROY M, Desmedt E, Deramoudt L, Vasseur M, et al
    Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma.
    Melanoma Res. 2024 Mar 15. doi: 10.1097/CMR.0000000000000965.
    PubMed     Abstract available
    
    
    
89. WANG P, Liu T, Zhang Q, Luo P, et al
    Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study.
    Melanoma Res. 2024 Mar 11. doi: 10.1097/CMR.0000000000000960.
    PubMed     Abstract available
    
    
    
90. NG CA, Luckett T, Mulhern B, Kee D, et al
    What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life.
    Melanoma Res. 2024 Mar 5. doi: 10.1097/CMR.0000000000000961.
    PubMed     Abstract available
    
    
    February 2024
91. DE PINTO G, Mignozzi S, La Vecchia C, Levi F, et al
    Global trends in cutaneous malignant melanoma incidence and mortality.
    Melanoma Res. 2024 Feb 21. doi: 10.1097/CMR.0000000000000959.
    PubMed     Abstract available
    
    
    
92. TEIXEIRA RJ, de Souza VG, Sorroche BP, Paes VG, et al
    Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio (tNLR) predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000958.
    PubMed     Abstract available
    
    
    
93. ZHANG W, Wang S
    Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
    Melanoma Res. 2024 Feb 16. doi: 10.1097/CMR.0000000000000957.
    PubMed     Abstract available
    
    
    
94. DE SMEDT J, Aura C, Van Kelst S, Janssen L, et al
    Clinical and genetic determinants of vitamin D receptor expression in cutaneous melanoma patients.
    Melanoma Res. 2024 Feb 13. doi: 10.1097/CMR.0000000000000929.
    PubMed     Abstract available
    
    
    
95. DELZENNE G, Boileau M, Jamme P, Farchi O, et al
    Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000955.
    PubMed     Abstract available
    
    
    
96. ERCAN A, Yalcin CE
    Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000956.
    PubMed     Abstract available
    
    
    
97. DIAZ MJ, Quach J, Song J, Milanovic S, et al
    Hypoxic transcriptomes predict survival and tumor-infiltrating immune cell composition in cutaneous melanoma.
    Melanoma Res. 2024 Feb 7. doi: 10.1097/CMR.0000000000000938.
    PubMed     Abstract available
    
    
    
98. GEIGER CE, Mrabet-Dahbi S, Berger I
    The BRAF and NRAS status among distinct metastases of malignant melanoma differ significantly independent of tissue origin and temporal occurrence. Possible effect on clinical relevance?
    Melanoma Res. 2024;34:85-87.
    PubMed    
    
    
    
99. ROSTER K, Thang C, Islam S, Lipner SR, et al
    Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies.
    Melanoma Res. 2024;34:84-88.
    PubMed    
    
    
    
100. DUARTE R, Trigo F, Luz I, Santos P, et al
     Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
     Melanoma Res. 2024;34:76-79.
     PubMed     Abstract available
     
     
     January 2024
101. DAVIDSON TM, Hieken TJ, Glasgow AE, Habermann EB, et al
     Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020.
     Melanoma Res. 2024 Jan 23. doi: 10.1097/CMR.0000000000000953.
     PubMed     Abstract available
     
     
     
102. KOSTAKI M, Plaka M, Befon A, Dessinioti C, et al
     Simultaneous melanomas in the setting of multiple primary melanomas.
     Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000954.
     PubMed     Abstract available
     
     
     
103. PARISA S, Amirhossein I, Hamed YS, Javad F, et al
     The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity.
     Melanoma Res. 2024 Jan 15. doi: 10.1097/CMR.0000000000000931.
     PubMed     Abstract available
     
     
     
104. KO B, Tao K, Brennan L, Rakhade S, et al
     Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
     Melanoma Res. 2024 Jan 5. doi: 10.1097/CMR.0000000000000945.
     PubMed     Abstract available
     
     
     December 2023
105. LOUVEAU B, Reger De Moura C, Jouenne F, Sadoux A, et al
     Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
     Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000950.
     PubMed     Abstract available
     
     
     
106. YEE J, Rosendahl C, Aoude LG
     The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective.
     Melanoma Res. 2023 Dec 22. doi: 10.1097/CMR.0000000000000951.
     PubMed     Abstract available
     
     
     
107. ROSHARDT PRIETO NM, Turko P, Zellweger C, Nguyen-Kim TDL, et al
     Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
     Melanoma Res. 2023 Dec 19. doi: 10.1097/CMR.0000000000000952.
     PubMed     Abstract available
     
     
     
108. YAN J, Wang H, Lu X, Li F, et al
     Development and validation of a nomogram for elderly patients with ulcerative melanoma.
     Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000940.
     PubMed     Abstract available
     
     
     
109. BAFALOUKOS D, Kouzis P, Gouveris P, Boukovinas I, et al
     Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter ch
     Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000949.
     PubMed     Abstract available
     
     
     
110. RICHTIG E, Nguyen VA, Koelblinger P, Wolf I, et al
     Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
     Melanoma Res. 2023 Dec 13. doi: 10.1097/CMR.0000000000000948.
     PubMed     Abstract available
     
     
     
111. SWITZER B, Puzanov I, Gandhi S, Repasky EA, et al
     Targeting beta-adrenergic receptor pathways in melanoma: how stress modulates oncogenic immunity.
     Melanoma Res. 2023 Dec 4. doi: 10.1097/CMR.0000000000000943.
     PubMed     Abstract available
     
     
     
112. PARISI R, Shah H, Everdell E, Feustel P, et al
     First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma.
     Melanoma Res. 2023;33:555-556.
     PubMed    
     
     
     
113. CARMONA-ROCHA E, Sullivan I, Yelamos O
     Vitiligo-like hypopigmentation induced by dabrafenib-trametinib: a potential marker for clinical response.
     Melanoma Res. 2023;33:553-555.
     PubMed    
     
     
     
114. TAN SX, Chong S, Rowe C, Claeson M, et al
     pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma.
     Melanoma Res. 2023;33:506-513.
     PubMed     Abstract available
     
     
     
115. MEYER SN, Simmons E, Studer AC, Rauen KA, et al
     Melanocytic neoplasms in neurofibromatosis type 1: a systematic review.
     Melanoma Res. 2023;33:437-446.
     PubMed     Abstract available
     
     
     
116. VIGNESWARAN G, Malalasekera W, Smith V, Gibson T, et al
     Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic Uveal Melanoma.
     Melanoma Res. 2023 Dec 1. doi: 10.1097/CMR.0000000000000947.
     PubMed     Abstract available
     
     
     November 2023
117. STAHLIE EHA, Zijlker LP, Wouters MWJM, Schrage YM, et al
     Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanoma.
     Melanoma Res. 2023 Nov 28. doi: 10.1097/CMR.0000000000000946.
     PubMed     Abstract available
     
     
     
118. MEZOLAKI NE, Baltas E, Ocsai HL, Varga A, et al
     Tumour regression predicts better response to interferon therapy in melanoma patients: a retrospective single centre study.
     Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000935.
     PubMed     Abstract available
     
     
     
119. KAHLER KC, Debus D, Schley G, Goppner D, et al
     Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS.
     Melanoma Res. 2023 Nov 13. doi: 10.1097/CMR.0000000000000908.
     PubMed     Abstract available
     
     
     
120. PAOLINO G, Carugno A, Rongioletti F, Ponzoni M, et al
     Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma.
     Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000942.
     PubMed     Abstract available
     
     
     
121. CHEN W, Yang C, Chen B, Xi M, et al
     Management of metastatic bone disease of melanoma.
     Melanoma Res. 2023 Nov 8. doi: 10.1097/CMR.0000000000000937.
     PubMed     Abstract available
     
     
     
122. TAIBO A, Paradela S, Suanzes-Hernandez J, Balboa-Barreiro V, et al
     Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000920.
     PubMed     Abstract available
     
     
     
123. GAMBICHLER T, Iordanou M, Becker JC, Susok L, et al
     Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000934.
     PubMed     Abstract available
     
     
     
124. KIM HE, Kim J, Park HK, Lee JB, et al
     Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000939.
     PubMed     Abstract available
     
     
     
125. BENESCH MGK, Skitzki JJ
     Impact of anesthesia choice in cutaneous melanoma surgery.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000936.
     PubMed     Abstract available
     
     
     
126. KOHL LM, Sumpter TL
     Melanomas and mast cells: an ambiguous relationship.
     Melanoma Res. 2023 Nov 2. doi: 10.1097/CMR.0000000000000932.
     PubMed     Abstract available
     
     
     October 2023
127. CAO Y, Afzal MZ, Gutmann EJ, Shirai K, et al
     Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
     Melanoma Res. 2023 Oct 13. doi: 10.1097/CMR.0000000000000925.
     PubMed     Abstract available
     
     
     
128. SADA I, Harada Y, Hiyama T, Mizukami M, et al
     Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma.
     Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000933.
     PubMed     Abstract available
     
     
     
129. RUBATTO M, Borriello S, Sciamarrelli N, Pala V, et al
     Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies.
     Melanoma Res. 2023 Oct 2. doi: 10.1097/CMR.0000000000000926.
     PubMed     Abstract available
     
     
     
130. PHAM JP, Dwyer L, Phan K, Menzies AM, et al
     Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
     Melanoma Res. 2023;33:434-436.
     PubMed    
     
     
     
131. OZLUK AA, Karateke M, Sanli UA, Karaca B, et al
     Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis.
     Melanoma Res. 2023;33:417-421.
     PubMed     Abstract available
     
     
     September 2023
132. BOUDREAU MW, Tonogai EJ, Schane CP, Xi MX, et al
     The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma.
     Melanoma Res. 2023 Sep 22. doi: 10.1097/CMR.0000000000000927.
     PubMed     Abstract available
     
     
     
133. SEGURA S, Podlipnik S, Boada A, Marti RM, et al
     Melanoma-specific survival in worse in the elderly: a multicentric cohort study.
     Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000923.
     PubMed     Abstract available
     
     
     
134. LIN Z, Shen H, Liu X, Ma W, et al
     Recent advances of artificial intelligence in melanoma clinical practice.
     Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000922.
     PubMed     Abstract available
     
     
     
135. UEMATSU M, Nakajima H, Hosono A, Kiyohara H, et al
     Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
     Melanoma Res. 2023 Sep 4. doi: 10.1097/CMR.0000000000000924.
     PubMed     Abstract available
     
     
     August 2023
136. LUO S, Xie C, Lin N, Lin D, et al
     Cost-effectiveness analysis of an orphan drug-tebentafusp in patients with metastatic uveal melanoma and a call for value-based pricing.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000919.
     PubMed     Abstract available
     
     
     
137. MATTEI J, Trindade EN, Chedid MF
     Mucosal melanoma: from molecular landscape to current treatment strategies.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000916.
     PubMed     Abstract available
     
     
     
138. MILEY DR, Andrews-Pfannkoch CM, Pulido JS, Erickson SA, et al
     Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000921.
     PubMed     Abstract available
     
     
     
139. LIU M, Lan Y, Zhang H, Zhang X, et al
     Telomere length is associated with increased risk of cutaneous melanoma: a Mendelian randomization study.
     Melanoma Res. 2023 Aug 25. doi: 10.1097/CMR.0000000000000917.
     PubMed     Abstract available
     
     
     
140. GJORUP CA, Pires da Silva I, Martin L, Stretch JR, et al
     Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
     Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000905.
     PubMed     Abstract available
     
     
     
141. AUGUSTYN K, Joseph J, Patel AB, Razmandi A, et al
     Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice.
     Melanoma Res. 2023 Aug 3. doi: 10.1097/CMR.0000000000000891.
     PubMed     Abstract available
     
     
     July 2023
142. GLINKINA KA, Teunisse AFAS, Gelmi MC, de Vries J, et al
     Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma.
     Melanoma Res. 2023 Jul 18. doi: 10.1097/CMR.0000000000000911.
     PubMed     Abstract available
     
     
     
143. FELICI C, Passarelli A, Cafforio P, Racanelli V, et al
     Lenalidomide arrests cell cycle and modulates PD1-dependent downstream mTOR intracellular signals in melanoma cells.
     Melanoma Res. 2023 Jul 12. doi: 10.1097/CMR.0000000000000913.
     PubMed     Abstract available
     
     
     
144. PELIZZARI G, Bertoli E, Buriolla S, Vitale MG, et al
     Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
     Melanoma Res. 2023 Jul 3. doi: 10.1097/CMR.0000000000000907.
     PubMed     Abstract available
     
     
     June 2023
145. GIRONI LC, Esposto E, Zottarelli F, Giorgione R, et al
     Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients.
     Melanoma Res. 2023 Jun 21. doi: 10.1097/CMR.0000000000000906.
     PubMed     Abstract available
     
     
     
146. HE K, Hong DS, Ke D, Kebriaei P, et al
     Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report.
     Melanoma Res. 2023 Jun 16. doi: 10.1097/CMR.0000000000000869.
     PubMed     Abstract available
     
     
     
147. ASSEFA W, Muluye S, Assefa A, Alemu Y, et al
     A glimpse at locally advanced melanomas in the settings of poverty: pathologists viewpoint.
     Melanoma Res. 2023 Jun 13. doi: 10.1097/CMR.0000000000000909.
     PubMed     Abstract available
     
     
     
148. KISISTOK J, Christensen DS, Rasmussen MH, Duval L, et al
     Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
     Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000903.
     PubMed     Abstract available
     
     
     
149. GARCIA-PEREZ O, Melgar-Vilaplana L, Sifaoui I, Garcia-Bello MA, et al
     Expression of angiogenic and lymphangiogenic genes in primary cutaneous melanoma: relationship with angiolymphatic invasion and disease-free survival.
     Melanoma Res. 2023 Jun 12. doi: 10.1097/CMR.0000000000000904.
     PubMed     Abstract available
     
     
     
150. AMARA SV, Grbic N, Melson G, Brem CE, et al
     Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection.
     Melanoma Res. 2023 Jun 5. doi: 10.1097/CMR.0000000000000902.
     PubMed     Abstract available
     
     
     
151. CHERSI F, Conforti C, Zalaudek I, Bazzacco G, et al
     Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient.
     Melanoma Res. 2023;33:262-263.
     PubMed    
     
     
     May 2023
152. AGNILA DRL, Huda TI, Eakins RA, Patel DN, et al
     Chemical features of melanoma tumor resident TRG CDR3s associated with better survival probabilities.
     Melanoma Res. 2023 May 23. doi: 10.1097/CMR.0000000000000899.
     PubMed     Abstract available
     
     
     
153. SHELLENBERGER RA, Gowda S, Kurn H, Albright J, et al
     Vitamin D insufficiency and serum levels related to the incidence and stage of cutaneous melanoma: a systematic review and meta-analysis.
     Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000897.
     PubMed     Abstract available
     
     
     
154. PHAM JP, On L, Ardolino L, Hurwitz J, et al
     Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis.
     Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000900.
     PubMed     Abstract available
     
     
     
155. YOO H, Park S, Kim SW
     Nodular type predominance of head and neck cutaneous malignant melanoma in Asian populations leads to poor outcome and low survival.
     Melanoma Res. 2023 May 18. doi: 10.1097/CMR.0000000000000901.
     PubMed     Abstract available
     
     
     
156. MATTAVELLI I, Patuzzo R, Galeone C, Pelucchi C, et al
     Potential risk factors, clinicopathological features and determinants of survival for multiple primary melanoma patients compared to single primary melanoma: a large single-center Italian study.
     Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000898.
     PubMed     Abstract available
     
     
     
157. OGATA D, Nishio S, Hatta N, Kaji T, et al
     Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan.
     Melanoma Res. 2023 May 8. doi: 10.1097/CMR.0000000000000894.
     PubMed     Abstract available
     
     
     April 2023
158. DIRVEN I, Vander Mijnsbrugge AS, Mignon S, Tijtgat J, et al
     Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
     Melanoma Res. 2023 Apr 28. doi: 10.1097/CMR.0000000000000895.
     PubMed     Abstract available
     
     
     
159. WONG CK, Dite GS, Spaeth E, Murphy NM, et al
     Melanoma risk prediction based on a polygenic risk score and clinical risk factors.
     Melanoma Res. 2023 Apr 24. doi: 10.1097/CMR.0000000000000896.
     PubMed     Abstract available
     
     
     
160. MOHAMMADI A, Najafi S, Amini M, Baradaran B, et al
     B7H6 silencing increases chemosensitivity to dacarbazine and suppresses cell survival and migration in cutaneous melanoma.
     Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000890.
     PubMed     Abstract available
     
     
     
161. STATHAKI MI, Kapsoritakis N, Michelakis D, Anagnostopoulou E, et al
     The impact of sentinel lymph node mapping with hybrid single photon emission computed tomography/computed tomography in patients with melanoma. Comparison to planar radioisotopic lymphoscintigraphy.
     Melanoma Res. 2023 Apr 12. doi: 10.1097/CMR.0000000000000893.
     PubMed     Abstract available
     
     
     
162. BRUNSGAARD EK, Bowles TL, Asare EA, Grossmann K, et al
     Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
     Melanoma Res. 2023 Apr 5. doi: 10.1097/CMR.0000000000000892.
     PubMed     Abstract available
     
     
     
163. CYBULSKA-STOPA B, Piejko K, Ostaszewski K, Dziura R, et al
     Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment.
     Melanoma Res. 2023 Apr 3. doi: 10.1097/CMR.0000000000000885.
     PubMed     Abstract available
     
     
     March 2023
164. MANZANO JL, Martin-Liberal J, Fernandez-Morales LA, Benitez G, et al
     Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study.
     Melanoma Res. 2023 Mar 28. doi: 10.1097/CMR.0000000000000888.
     PubMed     Abstract available
     
     
     
165. VUILLAMY C, Arnault JP, Fumery M, Mortier L, et al
     Clostridium difficile infection and immune checkpoint inhibitor-induced colitis in melanoma: 18 cases and a review of the literature.
     Melanoma Res. 2023 Mar 27. doi: 10.1097/CMR.0000000000000878.
     PubMed     Abstract available
     
     
     
166. YANG H, Zhou J, Li D, Zhou S, et al
     The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis.
     Melanoma Res. 2023 Mar 21. doi: 10.1097/CMR.0000000000000873.
     PubMed     Abstract available
     
     
     
167. BOILEAU M, Templier C, Massip E, Dehoux C, et al
     Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients.
     Melanoma Res. 2023 Mar 17. doi: 10.1097/CMR.0000000000000889.
     PubMed     Abstract available
     
     
     
168. PIGNE T, Levy M, Ducharme O, Dutriaux C, et al
     Real-life use of trametinib after immunotherapy failure in BRAF wild-type advanced melanoma.
     Melanoma Res. 2023 Mar 15. doi: 10.1097/CMR.0000000000000884.
     PubMed     Abstract available
     
     
     
169. BOILEAU M, Descarpentries C, Delzenne G, Trentesaux V, et al
     Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
     Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000882.
     PubMed     Abstract available
     
     
     
170. JASSO-SOSA VY, Lino-Silva LS, Escobar-Jimenez MG, Galvan-Bustillos JR, et al
     Prognosis of polypoid melanoma: a comparative study with non-polypoid melanomas.
     Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000886.
     PubMed     Abstract available
     
     
     
171. BERBERICH C, Mustafa M, Zhuwu Y, Gaa J, et al
     The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography.
     Melanoma Res. 2023 Mar 3. doi: 10.1097/CMR.0000000000000883.
     PubMed     Abstract available
     
     
     February 2023
172. KOMULAINEN J, Siiskonen H, Haimakainen S, Kanasuo E, et al
     Patients with a history of atopy have fewer cutaneous melanomas than those without atopy: a cross-sectional study in 496 patients at risk of skin cancers.
     Melanoma Res. 2023 Feb 28:e000887. doi: 10.1097/CMR.0000000000000887.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.